Cold virus hijacked to attack returning brain tumors in early trial
NCT ID NCT03896568
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study will enroll 36 patients to find the safest dose and watch for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- modified cold virus (DNX-2401) carried by donor stem cells
- What this could lead to
- If it works, this could point toward a new way to target and attack recurrent brain tumors that have few options.
- What could go wrong
- This is a very early phase 1 trial with only 36 people, focused on safety and dosing. The virus may not shrink tumors or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH-MUTANT GRADE 4 ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors